UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Amendment No. 1

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2025

Commission File Number 001-42915

 

Alps Group Inc

 

Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)

No. 1, Jalan 1/68F, Jalan Tun Razak

50400 Kuala Lumpur

Wilayah Persekutuan, Malaysia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No. 1 to Form 6-K (the “Amendment”) of Alps Group Inc (“Alps”) amends the report on Form 6-K previously filed with the Securities and Exchange Commission on October 30, 2025 (the “Original Form 6-K”), and is being filed solely to (i) revise the market effective date of Alp’s Ordinary Shares to October 31, 2025; (ii) update the trading symbol of Alps warrants to “ALPWF”; and (iii) update the press release announcing the closing of the Business Combination with Globalink Investment Inc., a Delaware corporation (“Globalink”). Except as set forth above, no other changes were made.

 

Except as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information in any other item of the Original Form 6-K or reflect any events that have occurred after the filing of the Original Form 6-K.

 

 

 

 

Closing of the Business Combination

 

On October 28, 2025, Alps Global Holding Pubco, a Cayman Islands exempted company (the “Company”), completed a business combination (the “Business Combination”) with Globalink Investment Inc., a Delaware corporation (“Globalink”). Upon the closing of the Business Combination, the Company changed its name to Alps Group Inc.

 

As a result of the Business Combination, the Company’s ordinary shares are expected to begin trading on Nasdaq under the symbol ALPS, and the Company’s warrants are expected to sold on the OTCID Basic Market under the symbol ALPWF, effective October 31, 2025.

 

The Business Combination was completed pursuant to the Merger Agreement dated as of January 30, 2024, as amended and restated on May 20, 2024, and further amended on March 6, 2025, April 18, 2025, and September 27, 2025, by and among the Company, Globalink and the other parties thereto.

 

On October 31, 2025, the Company issued a press release announcing the Closing. A copy of the press release is attached hereto as Exhibit 99.1.

 

The Company, Globalink and Alps Holdco are parties to subscription agreements (collectively, the “Subscription Agreements”) with certain investors (the “PIPE Investors”) pursuant to which the PIPE Investors purchased an aggregate of 310,788 Ordinary Shares of the Company for an aggregate subscription amount of US$3,107,875. The private placement was consummated substantially concurrently with the Closing. On October 10, 2025, the PIPE Investors, together with certain former shareholders of Globalink, also entered into the Amended and Restated Registration Rights Agreement with the Company pursuant to which the Company will, among other things, file a resale shelf registration statement on behalf of the stockholders no later than 60 days after the Closing. The Amended and Restated Registration Rights Agreement also provide certain demand registration rights and piggyback registration rights to the shareholders, subject to underwriter cutbacks and issuer blackout periods.

 

The foregoing description of the Amended and Restated Registration Rights Agreement is qualified in its entirety by the terms of the Amended and Restated Registration Rights Agreement attached hereto and incorporated herein as Exhibit 10.1.

 

Important Notice Regarding Forward-Looking Statements

 

This Report on Form 6-K contains certain “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about the Company’s perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of the completed business combination transaction, including the benefits of the proposed transaction, anticipated future financial and operating performance and results, plans for growth, and the expected management and governance of the combined company. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.

 

The forward-looking statements are based on the current expectations of the management of the Company, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statements. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to the Company’s businesses and strategies; the ability to recognize the anticipated benefits of the business combination; other risks and uncertainties included under the header “Risk Factors” in the registration statement on Form F-4, filed by the Company with the SEC; and in Globalink’s and the Company’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Company and its subsidiaries undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

 

 

 

 

Exhibit No.   Description
   
10.1   Amended and Restated Registration Rights Agreement, dated October 10, 2025, by and among Alps Global Holding Pubco, GL Sponsor LLC, Alps Life Sciences Inc., and certain individuals (Incorporated by reference to Exhibit 10.1 to the Form 6-K filed with the Securities and Exchange Commission on October 30, 2025).
99.1   Press Release dated October 31, 2025.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 31, 2025

 

  By: /s/ Tham Seng Kong
  Name: Tham Seng Kong
  Title: Chief Executive Officer and Director

 

 

 

 

Exhibit 99.1

 

 

Alps Announces Closing of Business Combination with Globalink Investment Inc.

 

Alps ordinary shares to list on the Nasdaq under the symbol “ALPS” on October 31, 2025

 

Kuala Lumpur, Malaysia / Newark, Delaware, October 31, 2025 – Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, and Globalink Investment Inc., a Delaware corporation and a special purpose acquisition company (“Globalink”), today jointly announced the successful completion (“Closing”) of their previously announced business combination (“Business Combination”).

 

The Business Combination was effected pursuant to the Amended and Restated Merger Agreement, originally dated January 30, 2024, as subsequently amended and restated on May 20, 2024, and further amended on March 6, 2025, April 18, 2025, and September 27, 2025 by and among Globalink, Alps Group, Alps Holdco, Alps Biosciences Merger Sub (“Merger Sub”), GL Sponsor LLC (as Parent Representative), and Dr. Tham Seng Kong (as Seller Representative).

 

The transaction, which was approved by Globalink’s stockholders on October 7, 2025, was completed through a two-step merger process comprising (1) a Redomestication Merger, pursuant to which Globalink merged with and into Alps Group, with Alps Group continuing as the surviving publicly traded entity, and (2) an Acquisition Merger, completed immediately thereafter, whereby Merger Sub merged with and into Alps Holdco, resulting in Alps Holdco continuing as the surviving entity and becoming a wholly owned subsidiary of Alps Group.

 

Following the Closing, the ordinary shares of Alps Group Inc will commence trading on the Nasdaq Stock Market under the ticker symbol “ALPS” on October 31, 2025, while the Company’s warrants will trade on the Over-the-Counter Market under the symbol “ALPWF.” On a consolidated basis, the combined company is expected to have an estimated enterprise value of approximately US$1.6 billion.

 

Leadership and Governance

 

After the Closing, the Company will operate under the name of Alps Group Inc and the Company’s headquarter will be located in Kuala Lumpur, Malaysia.

 

Effective upon Closing, the executive officers of Alps Holdco immediately prior to the Closing became the initial executive officers of Alps Group. Dr. Tham Seng Kong will serve as the Chief Executive Officer and Chairman of the Company’s Board of Directors.

 

 

 

 

Dr. Tham Seng Kong, Chief Executive Officer and Director of the Company, stated:

 

“Today marks a definitive milestone for ALPS as we join Nasdaq’s global stage. What began as a lifelong passion in genomics and cellular research has evolved into a mission to redefine the future of healthcare. From decoding the human genome to developing next-generation mRNA and personalized vaccines together with cellular therapies, our mission has always been to deliver predictive, preventive, and precision medicine to patients worldwide — at a cost that makes life-saving care accessible to all.”

 

Say Leong Lim, former Chief Executive Officer and Chairman of the Board of Directors of Globalink, remarked:

 

“We are pleased to have successfully consummated the Business Combination, marking the beginning of a new chapter for Globalink’s stockholders and the future growth potential of the Company. On behalf of the Board of Directors, I thank our working teams, partners and shareholders for their work and support.”

 

In connection with the Business Combination, Alps Group, Globalink, and Alps Holdco entered into subscription agreements with certain investors (“PIPE Investors”) for an aggregate subscription amount of approximately US$3,107,875, representing approximately 310,788 ordinary shares of Alps Group (“PIPE Investment”), which was consummated substantially concurrently with the Closing to support the Company’s growth strategy and working capital requirements.

 

Dr. Tham further noted:

 

“Our Nasdaq listing establishes ALPS on a global platform amplifying our brand, expanding our reach and, will also accelerate the development of our BioValley initiative, a cutting-edge biotechnology hub designed to foster a collaborative and supportive biotech ecosystem for innovators, investors, scientific talent and patients from across the globe. This is our answer to demonstrating Malaysia’s ability to incubate high-tech companies capable of competing on a global scale. We are committed to bridging gaps in the biotech industry fostering collaboration across research, manufacturing, and clinical applications, both regionally and globally.”

 

“At ALPS, we are not merely building a company we are building a transformative platform, uniting science, technology, and humanity to shape the next era of global healthcare”

 

Advisors

 

Darryl, Edward & Co. acted as legal advisor to Alps Global Holding Berhad. The Law Offices of Jenny Chen-Drake acted as U.S. legal counsel to Alps Group. Hunter Taubman Fischer & Li LLC acted as U.S. legal counsel to Globalink. Chardan acted as exclusive M&A and Capital Markets advisor to Globalink, and Sullivan & Worcester LLP acted as U.S. legal counsel to Chardan.

 

 

 

 

About Alps Group

 

Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group’s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable. .

 

About Globalink Investment Inc.

 

Globalink is led by Mr. Say Leong Lim, its Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors. Globalink is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

 

Forward-Looking Statements

 

This press release and any written or oral statements made by us in connection with this press release include forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that predict or indicate future events or trends, or the negative of these terms or comparable terminology, although not all forward-looking statements contain such words.

 

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, among others, statements regarding the Company’s business strategy, growth plans, financial outlook, market opportunities, and anticipated benefits of the recently completed Business Combination between the Company and Globalink.

 

Any forward-looking statements contained herein are based on the Company’s current plans, estimates, expectations, and projections, and are not guarantees of future performance. These statements represent management’s expectations as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to: (i) integration risks following completion of the Business Combination; (ii) the Company’s ability to execute its strategic and operational plans; (iii) potential litigation or regulatory proceedings relating to the Business Combination; (iv) the Company’s ability to retain and attract key personnel; (v) potential adverse reactions or changes to business relationships resulting from the closing of the Business Combination; (vi) general economic, financial, market, and political conditions; (vii) the Company’s access to capital and financing sources; and (viii) the other risks described under the captions “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in the Company’s filings with the SEC, including its registration statement on Form F-4, as well as subsequent filings with the SEC, which are available at www.sec.gov.

 

The Company undertakes no obligation to update or revise any forward-looking statements contained herein, whether as a result of new information, future events, or otherwise, except as required by applicable law.

 

Contacts:

 

Alps Group Inc

Dr. Tham Seng Kong

Email: investorrelations@alpsmedical.com

 

Globalink Investment Inc.

Lim Say Leong

Email: sllim@globalinkinv.com